|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Verma A, Warner SL, Vankayalapati H,
Bearss DJ and Sharma S: Targeting Axl and Mer kinases in cancer.
Mol Cancer Ther. 10:1763–1773. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J,
Kallop D, Ludlam MJ and Pei L: Axl as a potential therapeutic
target in cancer: Role of Axl in tumor growth, metastasis and
angiogenesis. Oncogene. 28:3442–3455. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hong CC, Lay JD, Huang JS, Cheng AL, Tang
JL, Lin MT, Lai GM and Chuang SE: Receptor tyrosine kinase AXL is
induced by chemotherapy drugs and overexpression of AXL confers
drug resistance in acute myeloid leukemia. Cancer Lett.
268:314–324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu L, Greger J, Shi H, Liu Y, Greshock J,
Annan R, Halsey W, Sathe GM, Martin AM and Gilmer TM: Novel
mechanism of lapatinib resistance in HER2-positive breast tumor
cells: Activation of AXL. Cancer Res. 69:6871–6878. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dunne PD, McArt DG, Blayney JK, Kalimutho
M, Greer S, Wang T, Srivastava S, Ong CW, Arthur K, Loughrey M, et
al: AXL is a key regulator of inherent and chemotherapy-induced
invasion and predicts a poor clinical outcome in early-stage colon
cancer. Clin Cancer Res. 20:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rankin EB, Fuh KC, Taylor TE, Krieg AJ,
Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ: AXL is
an essential factor and therapeutic target for metastatic ovarian
cancer. Cancer Res. 70:7570–7579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sainaghi PP, Castello L, Bergamasco L,
Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in
prostate carcinoma cell lines expressing the Axl receptor. J Cell
Physiol. 204:36–44. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shieh YS, Lai CY, Kao YR, Shiah SG, Chu
YW, Lee HS and Wu CW: Expression of axl in lung adenocarcinoma and
correlation with tumor progression. Neoplasia. 7:1058–1064. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sobin LH and Compton CC: TNM seventh
edition: What's new, what's changed: Communication from the
international union against cancer and the American Joint Committee
on cancer. Cancer. 116:5336–5339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Demarchi F, Verardo R, Varnum B,
Brancolini C and Schneider C: Gas6 anti-apoptotic signaling
requires NF-kappa B activation. J Biol Chem. 276:31738–31744. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shankar SL, O'Guin K, Kim M, Varnum B,
Lemke G, Brosnan CF and Shafit-Zagardo B: Gas6/Axl signaling
activates the phosphatidylinositol 3-kinase/Akt1 survival pathway
to protect oligodendrocytes from tumor necrosis factor
alpha-induced apoptosis. J Neurosci. 26:5638–5648. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Melaragno MG, Cavet ME, Yan C, Tai LK, Jin
ZG, Haendeler J and Berk BC: Gas6 inhibits apoptosis in vascular
smooth muscle: Role of Axl kinase and Akt. J Mol Cell Cardiol.
37:881–887. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee WP, Wen Y, Varnum B and Hung MC: Akt
is required for Axl-Gas6 signaling to protect cells from
E1A-mediated apoptosis. Oncogene. 21:329–336. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hasanbasic I, Cuerquis J, Varnum B and
Blostein MD: Intracellular signaling pathways involved in
Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart
Circ Physiol. 287:H1207–H1213. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tai KY, Shieh YS, Lee CS, Shiah SG and Wu
CW: Axl promotes cell invasion by inducing MMP-9 activity through
activation of NF-kappaB and Brg-1. Oncogene. 27:4044–4055. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vaughan CA, Singh S, Windle B, Yeudall WA,
Frum R, Grossman SR, Deb SP and Deb S: Gain-of-function activity of
mutant p53 in lung cancer through Up-regulation of receptor protein
tyrosine kinase Axl. Genes Cancer. 3:491–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
